1. My Clinical Approach to Acute Prostatitis
At my urology practice in Rhodes, acute bacterial prostatitis is one of the most common urological emergencies. Unlike chronic prostatitis — which develops gradually — ABP presents acutely within hours, with systemic features requiring immediate intervention.
My Three Core Principles (EAU 2025)
- Urine culture BEFORE starting any antibiotic. Starting empirical treatment without a specimen makes targeted therapy impossible if the first choice fails.
- Early recognition of urosepsis using the qSOFA score — an essential step in the first hours of assessment.
- Rational antibiotic use (antimicrobial stewardship): fluoroquinolones are no longer the automatic first choice due to rising resistance and EMA/MHRA restrictions.
2. What Is ABP & Pathogenesis
ABP occurs when bacterial pathogens — most commonly from the urinary tract or bowel flora — invade and multiply within the prostatic parenchyma, triggering an acute inflammatory response. Normally the prostate has defence mechanisms (antibacterial prostatic fluid, zinc, IgA), but these are overwhelmed when the microbial burden is high or a predisposing factor is present.
Routes of Infection
Ascending urethral infection
The most common route — bacteria ascend from the urethral flora.
Reflux of infected urine
Into prostatic ducts from the urethra.
Direct inoculation after urological procedures
Catheterisation, transrectal prostate biopsy, cystoscopy. Transperineal biopsy virtually eliminates this risk.
Haematogenous spread
From a distant infectious focus — uncommon.
3. Risk Factors & Causative Pathogens
Pathogens
ABP is predominantly caused by Gram-negative Enterobacterales, with Escherichia coli the leading organism (60–80%). Other common pathogens:
- Klebsiella pneumoniae
- Proteus mirabilis
- Pseudomonas aeruginosa (especially in nosocomial infections or post-instrumentation)
- Enterococcus spp.
- In sexually active young men: Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium
Risk Factors
| Risk Factor | Mechanism |
|---|---|
| Benign Prostatic Hyperplasia (BPH) | Urinary stasis promotes bacterial proliferation |
| Recent urinary catheterisation | Mechanical transfer of organisms |
| Recent transrectal prostate biopsy | Direct inoculation of the parenchyma |
| Recurrent urinary tract infections | Chronically colonised flora |
| Diabetes mellitus / Immunosuppression | Impaired bacterial clearance |
4. Symptoms & Clinical Presentation
ABP is characterised by rapid onset (within hours) and a clinical triad:
4.1 Systemic Features
- High fever (>38.5 °C) with rigors.
- Malaise, myalgia, arthralgia.
- Nausea or vomiting in severe cases.
- Tachycardia and tachypnoea — warning signs of urosepsis.
4.2 Lower Urinary Tract Symptoms (LUTS)
- Dysuria: severe burning or pain during urination.
- Urinary frequency and urgency.
- Nocturia.
- Weak stream or difficulty starting urination — potentially progressing to acute urinary retention (AUR).
- Gross haematuria in some cases.
4.3 Pelvic & Perineal Symptoms
- Severe perineal pain (between scrotum and anus) — the most characteristic symptom.
- Referred pain to the groin, scrotum or lower back.
- Sensation of rectal fullness or pressure.
- Painful ejaculation and, less commonly, haematospermia.
5. When Is It an Emergency — Recognising Urosepsis
EAU 2025 recommends the qSOFA score (quick Sepsis-related Organ Failure Assessment) for rapid identification of patients at risk of sepsis. Presence of ≥2 of the following indicates hospital admission is required:
Seek Urgent Medical Assessment Immediately When:
- Acute urinary retention (complete inability to urinate).
- High fever with rigors or signs of urosepsis (qSOFA ≥2).
- Gross haematuria with blood clots.
- Inability to take oral medications (persistent vomiting, dehydration).
- No improvement within 48–72 hours despite antibiotics — suspect abscess or resistant organism.
- Immunocompromised patients or poorly controlled diabetes.
6. Diagnostic Algorithm (EAU 2025)
6.1 Clinical Assessment
Medical history
Symptoms, recent catheterisation or biopsy, sexual activity, recent antibiotic use — critical for treatment selection.
Physical examination + DRE
The prostate is oedematous, warm and exquisitely tender on palpation.
Critical: Vigorous prostate massage for prostatic fluid is absolutely contraindicated in the acute phase. EAU 2025 classifies this as contraindicated as it may precipitate bacteraemia and urosepsis.
6.2 Laboratory Tests
Urinalysis
Leucocytes, nitrites, erythrocytes.
Midstream urine culture + sensitivity testing
Mandatory BEFORE antibiotic treatment. Targeted therapy is impossible without this.
FBC, CRP, creatinine, electrolytes
Assessment of disease severity and renal function.
Blood cultures
For high fever, rigors or suspected sepsis — strong recommendation EAU 2025.
PCR/NAAT
For Chlamydia trachomatis and Neisseria gonorrhoeae in sexually active young men.
6.3 Imaging
Not routine. Indicated when:
- No clinical improvement within 48–72 hours.
- Suspected prostate abscess.
- Possible obstructive cause or hydronephrosis.
First choice: Transrectal ultrasound (TRUS) or — in severe presentations — pelvic CT with contrast.
7. Antibiotic Treatment (EAU 2025)
ABP is treated as a systemic urinary tract infection in line with the updated EAU 2025 classification. Antibiotic selection is individualised based on severity, local resistance patterns, prior antibiotic exposure (last 6–12 months) and allergies.
7.1 Severe / Hospitalised Cases (Parenteral)
3rd-generation cephalosporins
Ceftriaxone, cefotaxime — first choice in many centres.
Broad-spectrum penicillins
Piperacillin/tazobactam — suitable for suspected Pseudomonas.
Fluoroquinolone (individualised)
Only if not used in the last 6 months and the patient has not been in a urological unit.
Aminoglycoside combination
Gentamicin, amikacin — in severe cases or suspected resistant organisms.
7.2 Mild to Moderate Cases (Oral)
Trimethoprim/sulfamethoxazole (TMP/SMX)
If local resistance <20%.
Fluoroquinolone (ciprofloxacin, levofloxacin)
Individualised — based on culture result and antibiotic history.
7.3 Duration of Treatment
| Category | Duration (EAU 2025) |
|---|---|
| Minimum duration | 14 days |
| Selected cases | 4 weeks (to prevent chronification) |
| Early discontinuation | Significantly increased risk of relapse and chronic prostatitis |
7.4 Fluoroquinolone Safety Warning (EMA / MHRA)
The EMA and MHRA have issued legally binding decisions restricting fluoroquinolone use due to serious adverse effects (tendinitis, Achilles tendon rupture, neuropathy, arrhythmias, aortic aneurysm). They should be avoided when alternatives exist and never used empirically in patients who received a fluoroquinolone in the previous 6 months.
7.5 Supportive Care
- Adequate hydration (oral or intravenous).
- Paracetamol or NSAIDs for fever and pain.
- For acute urinary retention: suprapubic catheter (cystostomy) preferred over urethral catheterisation to avoid worsening inflammation.
- Rest; avoid cycling and sexual activity during the acute phase.
8. Complications & Follow-up
Possible Complications
Urosepsis / Septic shock
Life-threatening — requires hospitalisation and parenteral treatment.
Prostate abscess
4–18% of cases. Suspected when fever persists despite appropriate antibiotics. Drainage required.
Acute urinary retention
Requires suprapubic catheterisation.
Epididymitis or orchitis
Due to ascending spread of infection.
Chronic Bacterial Prostatitis (CBP)
The most common complication of undertreatment — occurs in 5–10% of patients.
Follow-up Protocol
- Reassessment at 48–72 hours — if no improvement, suspect abscess or resistant organism.
- End-of-treatment review with urinalysis and urine culture.
- PSA review (if clinically indicated) 4–6 weeks after complete resolution.
- In patients with underlying BPH or recurrent infections, thorough evaluation for correctable factors.
Preventing Recurrence
- Address underlying bladder outlet obstruction (BPH, urethral strictures).
- Optimise control of diabetes and immunosuppressive conditions.
- Maintain adequate hydration and avoid urinary retention.
- In selected patients: individualised low-dose prophylactic antibiotic therapy.
- For men undergoing prostate biopsy: prefer the transperineal approach to eliminate sepsis risk.
9. FAQ — Frequently Asked Questions
How quickly does antibiotic treatment work?
Fever and pain typically begin to improve within 48–72 hours of starting the correct antibiotic. Complete resolution requires at least 14 days — premature discontinuation almost invariably leads to relapse or progression to chronic prostatitis.
Does acute prostatitis always require hospital admission?
No. Haemodynamically stable patients who can take oral medication and have adequate home support can be treated as outpatients. Hospitalisation is required for severe presentations, qSOFA ≥2, immunosuppression, or inability to take oral antibiotics.
Why should PSA not be checked during acute prostatitis?
Acute inflammation causes a transient, dramatic rise in PSA (often >20–50 ng/mL). This value does not reflect the true cancer risk and can lead to unnecessary investigations. PSA should be rechecked at least 4–6 weeks after complete recovery.
What does it mean if there is no improvement after 72 hours?
This is a red flag. Possible causes include a resistant organism, prostate abscess formation, an obstructive cause, or an incorrect initial antibiotic choice. Immediate reassessment with imaging is required.
Can acute prostatitis become chronic?
Yes, particularly when treatment is inadequate in duration or dosage. Approximately 5–10% of patients develop Chronic Bacterial Prostatitis. This is the most important reason to complete the full course of therapy.
Is it contagious? Should I avoid sexual activity?
ABP caused by enteric bacteria is not sexually transmitted. However, in younger men the cause may involve sexually transmitted pathogens (Chlamydia, Gonococcus) — in which case the partner should also be tested. Sexual activity should be avoided during the acute phase.
Should I take antibiotics I already have at home?
No. Self-treating with whatever antibiotics are available is one of the main drivers of antibiotic resistance and treatment failure. A urine culture must always be obtained first, and the antibiotic selected by a urologist.
Related Topics
Book an Appointment in Rhodes
High fever, rigors, severe perineal pain and difficulty urinating? Specialist urological assessment with urine culture and targeted antibiotic therapy at our practice in Rhodes, Greece.
References
- EAU Guidelines on Urological Infections 2025. European Association of Urology — uroweb.org
- Bonkat G, et al. EAU Guidelines on Urological Infections. Eur Urol 2025.
- EMA Fluoroquinolone Restrictions. European Medicines Agency, 2019 — Updated 2023.
- Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801–810.
- NHS: Prostatitis — nhs.uk
Medical Review
Dr. Marinos Vasilas, Urologist – Andrologist
Dr. Marinos Vasilas runs a private urology practice in Rhodes and Athens, specialising in the diagnosis and management of urological infections and prostatitis. He applies the EAU Guidelines on Urological Infections 2025 and the principles of antimicrobial stewardship.
Full profile
